.Attributes Medicine, Posted online: 16 September 2024 doi:10.1038/ s41591-024-03244-8In the observational SCRUM-Japan GOZILA study, after a mean follow-up of 11 months, patients with metastatic gastrointestinal lumps that acquired biomarker-matched treatments based upon spreading cyst DNA profiling revealed a greater medical advantage than those getting unmatched treatment.